 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) and Zura Bio (NASDAQ:ZURA - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two...

TScan Therapeutics (NASDAQ:TCRX) vs. Zura Bio (NASDAQ:ZURA) Financial Analysis

WALTHAM, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

This is a signal that TCRX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

TScan Therapeutics (TCRX, $7.92) RSI Indicator left the overbought zone on March 28, 2024

TScan Therapeutics (TCRX, $8.01) RSI Indicator left the overbought zone on March 22, 2024

TScan Therapeutics, Inc. (NASDAQ:TCRX  Free Report)  Stock analysts at HC Wainwright lifted their Q1 2024 earnings per share (EPS) estimates for shares of TScan Therapeutics in a...

HC Wainwright Weighs in on TScan Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:TCRX)

HC Wainwright reiterated their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX  Free Report) in a research report sent to investors on Thursday, Benzinga reports. The brokerage...

TScan Therapeutics (NASDAQ:TCRX) Receives Buy Rating from HC Wainwright

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

TScan Therapeutics price target raised by $2 at Barclays, here's why

Fourth Quarter and Full Year 2023 Financial Results and Business DevelopmentsRelated Stocks: TCRX...

TScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical Pipeline

Presented updated data from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies at the Tandem Meetings of ASTCT and CIBMTR; 8/8 (100%) patients in treatment arms are...

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Volume (M)	278,857.00
52-Wk High	$9.00
52-Wk Low	$1.62

TCRX Tscan Therapeutics Inc

About

Feed

News

Earnings

Fundamentals